U.S. Senate narrowly confirms Dr. Robert Califf to lead FDA for second
time
Send a link to a friend
[February 16, 2022]
By Ahmed Aboulenein
WASHINGTON (Reuters) -The U.S. Senate on
Tuesday voted to confirm Dr. Robert Califf as commissioner of the U.S.
Food and Drug Administration after some senators had argued his ties to
the pharmaceutical industry or views on birth control made him unfit for
the role.
Calif, 70, is a well-regarded cardiologist and researcher who takes the
helm at the FDA for a second time 13 months after it last had a
permanent leader.
His confirmation comes as the FDA reviews vaccines and treatments for
COVID-19. The agency oversees everything from medicine and medical
devices to food, tobacco and cosmetics.
Califf previously served as FDA commissioner from February 2016 until
the end of President Barack Obama's second term in January 2017.
He will take over from longtime FDA veteran Janet Woodcock, who has been
serving as acting commissioner. Woodcock congratulated Califf on Tuesday
and said she would be staying on as principal deputy.
His nomination by President Joe Biden was opposed by five of Biden's
fellow Democrats including Vermont Senator Bernie Sanders, who said
Califf's work with pharmaceutical companies made him unfit to regulate
the industry impartially, and West Virginia Senator Joe Manchin, who
criticized how the agency handled the opioid crisis under Califf's
leadership.
![](http://archives.lincolndailynews.com/2022/Feb/16/images/ads/current/LPL_small%201.gif)
"Dr. Califf was there five years ago. He's coming back. Nothing's
changed; 400,000 people have died (from opioids) since he was there,"
Manchin said before the vote.
Califf was confirmed by a narrow margin as six Republicans joined with
the remaining Democrats, resulting in 50 votes in favor and 46 against.
One senator voted present.
Senator Richard Burr of North Carolina, the ranking Republican on the
health committee, urged members of his party to support Califf before
the vote.
"He has the robust agency and private sector experience needed to help
build on the success of the FDA in helping Americans get back to normal
life," said Burr. "He's the leader we need today, but also for the
future."
The battle over Califf stood in stark contrast to the overwhelming
bipartisan support he received ahead of his first time in the role, when
89 senators voted to confirm him.
Previous Republican backers said they withdrew their support after
Califf told the Senate health committee in December that he trusted the
FDA to make the right decision as it considered easing abortion pill
restrictions, which it did two days later.
[to top of second column]
|
![](../images/021622pics/news_I15.jpg)
Food and Drug Administration Commissioner nominee Doctor Robert
Califf (C) arrives to testify during his nomination hearing before
the Senate Health, Education, Labor and Pensions Committee on
Capitol Hill in Washington, November 17, 2015. REUTERS/Gary
Cameron/File Photo
![](http://archives.lincolndailynews.com/2022/Feb/16/images/ads/current/heartland_lda_NOV2021.png) "It is clear that Dr. Califf will
not fight for life, and I cannot support his nomination," Republican
Senator Jim Inhofe of Oklahoma, who voted in favor of Califf in
2016, said in a statement after the vote.
'EXCITING MOMENT FOR BIRTH CONTROL'
Reproductive rights advocates lobbying for FDA approval of
over-the-counter oral contraceptives welcomed Califf's confirmation.
"I think it's a really exciting moment for birth control pills,"
Victoria Nichols, project director of the Free the Pill campaign,
told Reuters.
Cardiology group the American Heart Association and patient
advocates UsAgainstAlzheimer's both issued statements welcoming
Califf's confirmation, as did PhRMA, the leading pharmaceutical
industry trade group.
John Serio, partner at law firm Withersworldwide who focuses on the
pharmaceutical industry, said Califf brings unique experience to the
role.
"You have somebody now heading the agency that understands the drug
discovery process in great detail and understands it not only from
an industry standpoint, but also from the agency standpoint," he
said.
Califf has co-authored papers with industry executives, served as a
consultant for drugmakers, and following his first stint as FDA
chief was hired by Google parent Alphabet Inc in 2019 as head of
clinical policy and strategy across its Google Health and Verily
Life Sciences enterprises.
Califf had previously advised Verily executives on clinical matters
for potential products.
![](http://archives.lincolndailynews.com/2022/Feb/16/images/ads/current/graue_sda_042021.png)
Califf has been on the board of drugmaker Cytokinetics Inc since
February 2018, the company's website shows, and has received over
$93,000 in consulting and other fees between 2014 and 2019 from nine
drugmakers, government records show.
(Reporting by Moira Warburton and Ahmed Aboulenein; Editing by Bill
Berkrot)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |